Tango Therapeutics, Inc.

NasdaqGM:TNGX Stock Report

Market Cap: US$334.1m

Tango Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?


Recent Insider Transactions

NasdaqGM:TNGX Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
18 Nov 24BuyUS$74,000Mace RothenbergIndividual20,000US$3.78
07 Nov 24SellUS$8,435,743EcoR1 Capital, LLCCompany2,700,000US$3.29
06 Nov 24SellUS$9,671,200Boxer Capital Management, LLCCompany3,080,000US$3.14
25 Oct 24SellUS$4,348,710Boxer Capital Management, LLCCompany633,000US$6.87
22 Oct 24SellUS$6,101,250Boxer Capital Management, LLCCompany875,000US$7.05
13 Sep 24SellUS$709,756Third Rock Ventures, LLCCompany67,400US$10.53
05 Sep 24SellUS$867,135Third Rock Ventures, LLCCompany75,000US$11.56
30 Aug 24SellUS$2,029,703Third Rock Ventures, LLCCompany175,000US$11.60
27 Aug 24SellUS$288,665Third Rock Ventures, LLCCompany25,000US$11.55
19 Aug 24SellUS$2,835,368Third Rock Ventures, LLCCompany285,000US$10.09
01 Aug 24SellUS$2,316,494Third Rock Ventures, LLCCompany235,000US$9.93
26 Jul 24SellUS$491,950Third Rock Ventures, LLCCompany50,000US$9.84
25 Jul 24SellUS$2,955,931Third Rock Ventures, LLCCompany300,599US$9.87
23 Jul 24SellUS$3,793,446Third Rock Ventures, LLCCompany387,740US$9.79
18 Jul 24SellUS$1,878,479Third Rock Ventures, LLCCompany191,490US$9.81
17 Jul 24SellUS$5,386,339Third Rock Ventures, LLCCompany550,171US$9.79
02 Jul 24SellUS$2,055,314MVA Associates, LLCCompany234,731US$8.87
07 Jun 24SellUS$985,880MVA Associates, LLCCompany140,000US$7.24
03 May 24SellUS$1,580,850MVA Associates, LLCCompany210,000US$7.61
20 Feb 24SellUS$1,950,000Third Rock Ventures, LLCCompany162,500US$12.00
07 Feb 24SellUS$46,900Daniella BeckmanIndividual3,725US$12.62
07 Feb 24SellUS$115,052Barbara WeberIndividual9,138US$12.62
07 Feb 24SellUS$105,395Adam CrystalIndividual8,371US$12.62
07 Feb 24SellUS$34,951Douglas BarryIndividual2,776US$12.62

Insider Trading Volume

Insider Buying: TNGX insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

What is the ownership structure of TNGX?
Owner TypeNumber of SharesOwnership Percentage
Private Companies326,8860.298%
Individual Insiders1,911,6461.74%
Public Companies4,854,4434.43%
Hedge Funds21,011,73519.2%
VC/PE Firms32,893,66730%
Institutions48,590,74144.3%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Top 25 shareholders own 94.03% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
15.7%
Third Rock Ventures, LLC
16,859,075US$52.4m-12.2%14.17%
9.9%
EcoR1 Capital, LLC
10,630,736US$33.1m-20.3%1.25%
9.78%
TCG Crossover Management, LLC
10,500,612US$32.7m0%3.34%
9.66%
Boxer Capital Management, LLC
10,380,999US$32.3m0%no data
5.15%
Nextech Invest Ltd.
5,533,980US$17.2m0%2.99%
4.69%
T. Rowe Price Group, Inc.
5,039,331US$15.7m5.62%no data
4.65%
Southpoint Capital Advisors LP
5,000,000US$15.5m-5.24%0.33%
4.52%
Gilead Sciences, Inc.
4,854,443US$15.1m0%no data
4.06%
BlackRock, Inc.
4,361,335US$13.6m9.37%no data
3.39%
The Vanguard Group, Inc.
3,645,303US$11.3m10.7%no data
2.52%
Bain Capital Life Sciences Investors, LLC
2,712,008US$8.4m-6.25%1.06%
2.51%
Citadel Advisors LLC
2,694,125US$8.4m119%0.01%
2.5%
Balyasny Asset Management L.P.
2,687,196US$8.4m870%0.02%
2.42%
Artal Group S.A.
2,603,897US$8.1m3.34%0.24%
2.16%
State Street Global Advisors, Inc.
2,318,208US$7.2m26.8%no data
2.14%
Adage Capital Management, L.P.
2,294,206US$7.1m0%0.01%
1.43%
Deerfield Management Company, L.P. Series C
1,540,000US$4.8m0%0.08%
1.3%
Barbara Weber
1,397,440US$4.3m0%no data
1.27%
Geode Capital Management, LLC
1,368,262US$4.3m11.6%no data
1.11%
Casdin Capital, LLC
1,188,349US$3.7m0%0.24%
0.7%
Baker Bros. Advisors LP
750,000US$2.3m0%0.02%
0.66%
ArrowMark Colorado Holdings, LLC
708,385US$2.2m0%0.03%
0.66%
Bessemer Investment Management LLC
708,384US$2.2m0%no data
0.59%
Samsara BioCapital LLC
630,000US$2.0m0%0.31%
0.56%
Superstring Capital Management LP
599,048US$1.9m418%1.97%

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/31 07:55
End of Day Share Price 2025/01/31 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Tango Therapeutics, Inc. is covered by 11 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Peter LawsonBarclays
Yuan ZhiB. Riley Securities, Inc.
Eric SchmidtCantor Fitzgerald & Co.